ISU ABXIS

Company Overview

Founded in 2001 with the goal of becoming a global axis of antibody therapeutics development—as reflected in our name ISU ABXIS (Anti-Body + aXIS)—we are an innovative biopharmaceutical company developing novel therapeutics for immuno-oncology and rare diseases.

Through our consistent dedication to antibody therapeutics development, ISU ABXIS has built a diverse new drug pipeline including immuno-oncology and rare disease therapeutics, leading the domestic biopharmaceutical industry as a company specialized in biopharmaceutical development. With our antibody development technology, we are realizing our vision as a global biopharmaceutical company that provides new treatment options to cancer and rare disease patients worldwide, adding abundance and convenience to life and creating a better future.

Vision

ISU ABXIS will grow into a global biopharmaceutical company that adds abundance and convenience to people’s lives by developing innovative therapeutics for immuno-oncology and rare diseases.

ISU Core Purpose

Creating a Beautiful Future That Enriches Lives with Abundance and Convenience

ISU Core Value

Trust

Honesty &
Responsibility

Challenge

Higher &
Faster

Empathy

Understand Together &
Grow Together

ISU ABXIS Values

Passion Confidence and positive thinking that we can turn the impossible into possible with a challenging spirit.
Goal Achievement An extraordinary commitment to execute the goals set by the organization and individual, and to persist until completion.
Autonomy & Responsibility Activists who take responsibility for performance within the organization and prove their own value through results.
Innovation Readiness to change everything that was taken for granted, redefine the present, and completely transform the rules of the game.

ISU ABXIS STRENGTHS

First Developed
Korea’s 1st Antibody Therapeutic
Proprietary Products
3 Launched
Research Areas
Oncology, Immunology & Rare Diseases
R&D Projects
7
In-house Manufacturing
3 Suites Operating

About Us